Quanterix Corp at Goldman Sachs Alzheimer's Disease Day Transcript
All right. We'll get started here as people kind of pick up their lunches and come in, but good afternoon. My name is Matt Sykes. I'm the life science tools and diagnostics analyst at Goldman Sachs. And I have the pleasure of welcoming Masoud Toloue, President and CEO of Quanterix to my right; and Joel Braunstein, Co-Founder and CEO of C2N on further to my right. These are 2 companies which are at the forefront of developing commercializing blood-based biomarker testing for Alzheimer's disease. Masoud and Joel, welcome.
Hey, Matt.
So this is a discussion that I've been selfishly looking forward to for some time. Last week, my team published a deep dive on blood biomarker testing for Alzheimer's, where we developed a market model for Alzheimer's testing outlining a potential
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |